Amplia Therapeutics Highlights Potential for Combination Therapy with KRAS Inhibition in Pancreatic Cancer

Following significant data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, Amplia Therapeutics outlined potential opportunities to combine its FAK inhibitor narmafotinib with emerging KRAS inhibitors like daraxonrasib. The CEO emphasized that these developments position Amplia as a key player in advancing treatment for pancreatic cancer.

By Amplia Therapeutics Limited · GlobeNewsWire · June 22, 2026, 12:45 UTC

Tickers: $RVMD

Topics: cancer treatment KRAS inhibition pancreatic cancer pharmaceuticals

Read the full article at GlobeNewsWire

More Health news

Data Suggests United States May Lose Measles Elimination Status The Verge · November 11, 2026, 19:48 UTC
Rising U.S. Measles Outbreaks Pose Significant Economic Burden CNBC · November 11, 2026, 12:00 UTC
FDA Issues Not Approvable Letter for NovoCure's Optune Mya Motley Fool · November 10, 2026, 18:50 UTC
Immunovant Reports Q2 2026 Financial Results and IMVT-1402 Clinical Data Motley Fool · November 10, 2026, 01:43 UTC
Royalty Pharma Poised to Benefit from Revolution Medicines' FDA-Approved Pancreatic Cancer Drug Motley Fool · November 8, 2026, 15:15 UTC
Acumen Pharmaceuticals Expects Phase II Alzheimer's Trial Results in November 2026 Motley Fool · November 5, 2026, 01:48 UTC
Moderna and Merck Face Manufacturing Challenges for Promising Personalized Cancer Vaccine Motley Fool · November 3, 2026, 20:52 UTC
Amgen's Imdelltra Shows Significant Efficacy in Advanced Lung Cancer Treatment Motley Fool · November 2, 2026, 17:25 UTC
American Association for Physician Leadership Releases New Book on Systems Thinking and Strategic Change PR Newswire · October 30, 2026, 12:51 UTC
Pennsylvania Reports Nearly 1,400 Measles Cases and Five Deaths Seeking Alpha · October 29, 2026, 16:18 UTC